Lead Product(s) : Ocrelizumab,Diphenhydramine,Methylprednisolone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche Updates Phase III OCREVUS High Dose Study in Relapsing MS Patients
Details : Ocrevus (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage.
Product Name : Ocrevus
Product Type : Antibody
Upfront Cash : Inapplicable
April 02, 2025
Lead Product(s) : Ocrelizumab,Diphenhydramine,Methylprednisolone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ocrelizumab,Desloratadine,Dexamethasone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche’s Subcutaneous OCREVUS Shows Strong One-Year Results in MS Patients
Details : Ocrevus (ocrelizumab) is a twice-yearly subcutaneous injection designed to target CD20-positive B cells for treating progressive and relapsing multiple sclerosis.
Product Name : Ocrevus
Product Type : Antibody
Upfront Cash : Inapplicable
April 17, 2024
Lead Product(s) : Ocrelizumab,Desloratadine,Dexamethasone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Aducanumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Biogen
Deal Size : $380.0 million
Deal Type : Termination
Neurimmune Regains Global Rights to Brain Amyloid Depleter for Alzheimer’s Treatment
Details : Under the termination, Neurimmune regained global rights to aducanumab, a recombinant human antibody developed to deplete brain amyloid, for the treatment and prevention of Alzheimer’s disease.
Product Name : Aduhelm
Product Type : Antibody
Upfront Cash : Undisclosed
January 31, 2024
Lead Product(s) : Aducanumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Biogen
Deal Size : $380.0 million
Deal Type : Termination
Lead Product(s) : Crenezumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Genentech
Deal Size : $418.0 million
Deal Type : Termination
AC Immune to Regain Global Rights to Crenezumab and Semorinemab
Details : AC Immune regains global rights to anti-amyloid beta antibody RO5490245 (crenezumab) and anti-Tau antibody semorinemab, both evaluated for Alzheimer’s disease.
Product Name : MABT5102A
Product Type : Antibody
Upfront Cash : Undisclosed
January 22, 2024
Lead Product(s) : Crenezumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Genentech
Deal Size : $418.0 million
Deal Type : Termination
Lead Product(s) : Dexamethasone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OCS-01 (dexamethasone) is a glucocorticoid receptor agonist, which is being evaluated in phase 3 clinical trials for the treatment of inflammation and pain following cataract surgery.
Product Name : OCS-01
Product Type : Steroid
Upfront Cash : Inapplicable
December 20, 2023
Lead Product(s) : Dexamethasone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fenebrutinib is an investigational oral, reversible and non-covalent Bruton’s tyrosine kinase (BTK) inhibitor that is brain penetrant and reduces brain lesions in people with relapsing multiple sclerosis (RMS).
Product Name : RG7845
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2023
Lead Product(s) : Fenebrutinib
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Demerger
Novartis Confirms Sandoz Spin-off for October 4, 2023
Details : Through the divestment, Novartis will complete its transformation to become a leading, focused medicines company and Sandoz will work on its generic and biosimilars pipeline, including SB17 a proposed biosimilar to Stelara (ustekinumab).
Product Name : SB17
Product Type : Antibody
Upfront Cash : Undisclosed
September 25, 2023
Lead Product(s) : Ustekinumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Novartis Pharmaceuticals Corporation
Deal Size : Undisclosed
Deal Type : Demerger
Lead Product(s) : Natalizumab
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Polpharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Sandoz Receives Positive CHMP Opinion for Multiple Sclerosis Biosimilar Natalizumab
Details : Natalizumab biosimilar is mAB that acts as α4 integrin antagonist to prevent leukocyte trafficking into central nervous system, demonstrated high efficacy in Phase III trials by reducing annualized relapse rate, preventing multiple sclerosis lesion accu...
Product Name : Tyruko
Product Type : Antibody
Upfront Cash : Inapplicable
July 24, 2023
Lead Product(s) : Natalizumab
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Polpharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ocrelizumab,Desloratadine,Dexamethasone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : OCREVUS (ocrelizumab) is a humanised monoclonal antibody designed to target CD20-positive B cells, which is being investigated as a a 10-minute subcutaneous injection, for the treatment of multiple sclerosis.
Product Name : Ocrevus
Product Type : Antibody
Upfront Cash : Inapplicable
July 13, 2023
Lead Product(s) : Ocrelizumab,Desloratadine,Dexamethasone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ACT-108475 (clazosentan) is a fast-acting, endothelin A (ETA) receptor antagonist, that Idorsia has developed as a continuous intravenous infusion for the prevention of clinical deterioration due to delayed cerebral ischemia (DCI) in patients following a...
Product Name : ACT-108475
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 02, 2023
Lead Product(s) : Clazosentan Sodium
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable